Century Therapeutics Inc
2 ballot items.
Two proposals are being voted on at Century Therapeutics' 2026 Special Meeting: a discretionary reverse stock split to 1-for-5 to 1-for-30 with Board discretion, and an adjournment to seek additional votes.
Follow how the vote landed and what changed on Century Therapeutics Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
On the ballot2
- 1
Approval of an amendment to the Charter to effect a reverse stock split of our outstanding shares of Common Stock by a ratio of any whole number between 1-for-5 and 1-for-30, the implementation and timing of which shall be subject to the discretion of the Board
ManagementBoard: FORAuthorize the Board to effect a reverse stock split in the range 1-for-5 to 1-for-30, at its discretion, which would adjust the number of shares outstanding and potentially impact equity awards, with the aim of regaining Nasdaq listing compliance and improving marketability and investor perception.
- 2
Approval of adjournment of the Special Meeting to the extent there are insufficient votes at the Special Meeting to approve the preceding proposal or to establish a quorum
ManagementBoard: FORAuthorize adjourning the Special Meeting to permit solicitation of additional proxies if there are insufficient votes to approve Proposal 1 or to establish a quorum.
Nominees on the ballot
Top institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | TCG Crossover Management, LLC | 9.8% | 17,754,430 | $39M |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 9.8% | 17,754,430 | $40M |
| 3 | Versant Venture Management, LLC | 6.7% | 12,166,109 | $27M |
| 4 | Deep Track Capital, LP | 5.3% | 9,487,745 | $21M |
| 5 | Commodore Capital LP | 4.8% | 8,695,652 | $20M |
| 6 | RTW INVESTMENTS, LP | 4.8% | 8,695,652 | $20M |
| 7 | Venrock Adviser, LLC | 4.8% | 8,695,652 | $20M |
| 8 | Point72 Asset Management, L.P.Activist | 3.3% | 5,964,678 | $13M |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 3.2% | 5,686,204 | $13M |
| 10 | BALYASNY ASSET MANAGEMENT L.P. | 2.8% | 5,017,733 | $11M |
Other Healthcare sector meetings6
Upcoming shareholder meetings at Century Therapeutics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Frequently asked questions
- When is the Century Therapeutics Inc 2026 special meeting?
- Century Therapeutics Inc (IPSC) holds its 2026 special shareholder meeting on Thursday, January 22, 2026.
- What is the record date for the Century Therapeutics Inc 2026 meeting?
- The record date for the Century Therapeutics Inc 2026 meeting is Tuesday, November 25, 2025. Shareholders of record on or before that date are eligible to vote.
- What proposals will shareholders vote on at the Century Therapeutics Inc 2026 meeting?
- Shareholders will vote on 2 proposals at the Century Therapeutics Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.